Compare SEV & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEV | BMEA |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | 46 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.9M | 91.1M |
| IPO Year | N/A | 2021 |
| Metric | SEV | BMEA |
|---|---|---|
| Price | $2.20 | $1.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.83 |
| AVG Volume (30 Days) | 285.6K | ★ 628.6K |
| Earning Date | 05-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17,757.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.29 | $0.87 |
| 52 Week High | $11.24 | $2.99 |
| Indicator | SEV | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 57.28 | 48.75 |
| Support Level | $1.97 | $1.21 |
| Resistance Level | $2.45 | $1.44 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 70.00 | 62.79 |
Aptera Motors Corp engages in the development, production, and distribution of energy efficient solar-powered, battery-electric vehicles. The company has designed the Aptera vehicle to provide up to an estimated 40 miles per day by collecting energy from the sun and storing it in its proprietary battery pack. The company operates as a single reportable segment focused on the development of solar electric vehicles.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.